RE:RE:Trenibrorher@w:o - Novartis&Sirona?! Trenibrother also seems to have a simple explanation for this:
It is quite simple:
Company A is interested in an active ingredient of company B. Now, it is not unusual in the pharmaceutical industry to record possible contract negotiations intended at a later point in time, for example in a LOI (letter of interest).
Furthermore, confidentiality, due diligence, etc. can be agreed here. However, an LOI is not subject to notification.
In the case of Company B's substance, however, it is still in development and a certain efficacy has not been researched at all at the time of the interest and is therefore anything but proven. In the case of TFC-039, we are talking about a completed phase 1 trial by Wangbang with correspondingly available data material.
Company A may consider the existing data material to be promising and agree an LOI (letter of intent) with company B, of which we know nothing.
Company A is not at all able to assess the benefit and possible success at the current stage of development and carries out due diligence (DD). This includes, among other things, clinical studies, in this case phase 2 and phase 3 studies, which is why such a DD can sometimes take a long time.
So everything is possible and legal.